WaveMan
WaveMan · Company
CYPH · Cypherpunk Technologies Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CYPH Cypherpunk Technologies (CYPH) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001509745
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
30
13F, latest reported quarter

What the filings say about CYPH

Insiders, 180 days
-$888.9K net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$32.3K
1 notice

Cypherpunk Technologies insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CYPHERPUNK TECHNOLOGIES INC. insiders sold a net $888.9K of stock across 9 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Oei Khing Djien
Director
SELL
2026-09-25 SEC
168,750
$661.5K
-14.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • 2 other insiders sold within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Oei Khing Djien sold about $661.5K of CYPH on Sep 25, 2026; 2 other insiders sold within 30 days and 30 funds added in the latest 13F quarter.
Martin Patricia A.
Director
SELL
2026-09-25 SECtraded 2026-09-23
50,000
$193.0K
-14.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 42.1% of the 118,750 shares held after it.
  • 2 other insiders sold within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Martin Patricia A. sold about $193.0K of CYPH on Sep 23, 2026; 2 other insiders sold within 30 days and 30 funds added in the latest 13F quarter.
Dietz Thomas John
Director
SELL
2026-08-27 SECtraded 2026-08-26
20,000
$34.4K
+65.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 15.1% of the 132,500 shares held after it.
  • 2 other insiders sold within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Dietz Thomas John sold about $34.4K of CYPH on Aug 26, 2026; 2 other insiders sold within 30 days and 30 funds added in the latest 13F quarter.
Mirabelli Christopher
Director
SELL
2026-03-30 SECtraded 2026-03-26
60,000
$42.6K
+256.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Nov 17, 2025.
  • The trade is 46.0% of the 130,376 shares held after it.
  • No other insider sold within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mirabelli Christopher sold about $42.6K of CYPH on Mar 26, 2026; 30 funds added in the latest 13F quarter.
Mirabelli Christopher
Director
SELL
2025-11-19 SECtraded 2025-11-17
414,479
$1.3M
-3.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 19404.4% of the 2,136 shares held after it.
  • 2 other insiders sold within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mirabelli Christopher sold about $1.3M of CYPH on Nov 17, 2025, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 30 funds added in the latest 13F quarter.
9 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 4 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$888.9K over 180 days
-$888.9K over 90 days
below 61% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
30 funds bought in last quarter
below 62% of Pharma & Biotech
Revenue
+0.0% year over year
below 56% of Pharma & Biotech
Margin
321.5% net margin
more than 98% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
21.1% of the float short (float per yahoo 2026-10-27) · 1.2 days to cover · settled 2026-10-15
more than 83% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CYPH

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+504.7%12M
-13%+252%+516%+780%2025-102025-122026-022026-042026-062026-082026-10 2025-11-17 · Mirabelli Christopher sold $1.3M2025-11-17 · ONSI DOUGLAS E sold $1.3M2025-11-17 · Mirabelli Christopher sold $822.2K2025-11-17 · CAVANAUGH JAMES H sold $822.2K2025-11-17 · ONSI DOUGLAS E sold $822.2K2026-09-25 · Oei Khing Djien sold $661.5K2026-09-23 · Martin Patricia A. sold $193.0K2026-03-26 · Mirabelli Christopher sold $42.6K2026-08-26 · Dietz Thomas John sold $34.4K2026-08-26 · Dietz Thomas John filed to sell $32.3K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CYPH: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
3,887,574 sh
$2.4M
BlackRock, Inc.
2,622,823 sh
$1.6M
JANE STREET GROUP, LLC
1,701,926 sh
$1.0M
GEODE CAPITAL MANAGEMENT, LLC
1,173,737 sh
$718.8K
UBS Group AG
1,127,366 sh
$689.9K

Congress trades in CYPH

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CYPH planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Dietz Thomas John
Filed 2026-08-26
$32.3K

CYPH mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Health Care ETF
$17.1K position · as of 2026-06-30
0.0%
Victory Extended Market Index Fund
$5.9K position · as of 2026-07-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$702.9K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$299.2K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$59.1K position · as of 2026-05-31
0.0%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND
$47.1K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $888.9K sold by insiders over 180 days, 30 funds added last quarter, $32.3K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CYPH financials

Revenue growth
0.0%
XBRL, annual
Net margin
321.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.5M
four quarters, 2021-01-01 to 2021-12-31
Net margin, TTM
-46.6%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-1.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-0.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
effective tax rate 171%, not meaningful
Return on capital employed
-24.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
5.05x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$41.1M-$70.1M-$87.0M-$56.8M
Net income$5.0M-$68.0M-$81.0M-$54.6M
EPS (diluted)0.07-1.81-3.98-4.82
Operating cash flow-$43.9M-$60.3M-$43.8M-$49.0M
Cash$14.0M$47.2M$70.6M$65.5M
SEC XBRL, fiscal years, as known on 2026-10-28

CYPH Stock Sonar score 5/7 axes

Find similar shapesCompare

CYPH ranks highest on profitability (77th percentile) and growth (44th), and lowest on risk and compliance (8th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
77
Inputs
  • Return on equity-1.0% · 81 pct, sector of 545
  • Return on assets-0.9% · 81 pct, sector of 691
  • Return on invested capitaleffective tax rate 171%, not meaningful
  • Return on capital employed-24.2% · 71 pct, sector of 576
Growth
44
Inputs
  • Revenue growth, YoY+0.0% · 44 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
18
Inputs
  • Net Form 4 buying (codes P and S), 180d-$889K · 37 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
38
Inputs
  • Funds adding, latest quarter30 · 38 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
8
Inputs
  • Short interest, % of float+21.1% · 13 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+63.6% · 3 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CYPH filings, in plain words

Are Cypherpunk Technologies insiders buying or selling CYPH?

In the 180 days to 2026-10-28, Cypherpunk Technologies insiders were net sellers, a net $888.9K across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of CYPH?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $32.3K of stock; the latest, by Dietz Thomas John, was filed 2026-08-26.

Read the full summary

In the 180 days to 2026-10-28, Cypherpunk Technologies insiders were net sellers of CYPH, a net $888.9K across purchases and sales reported on Form 4 by 3 sellers. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $32.3K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies